Parkinson's disease (PD) is a chronic neurodegenerative disorder of the central nervous system, which characteristic symptoms manifest as a result of the lack of the neurotransmitter dopamine in the part of the brain responsible for the control of movement. The urinary system consists of two kidneys, two ureters, the bladder and the urethra. Urinary tract organs are involved in regulating the volume and composition of body fluids. The process of bladder control is very complex and depends on the integrity of the central and peripheral nervous system. It is not surprising that in patients who have PD, with damage to multiple areas of the peripheral and central nervous system, there is a dysfunction of the bladder. The urinary dysfunctions are in most cases occur in the form of bladder detrusor hyperactivity. The most widely accepted theory is that the basal ganglia inhibit the micturition reflex in normal conditions via D1 receptors and that cell depletion in the SNc in PD results in the loss of the D1 mediated inhibition and thereby leads to overactivity of the detrusor. Difficulties removing urine can be caused by sphincter that tends to contraction, when the bladder is ready for emptying or by the bladder muscle that is too weak to eject urine. Recent studies suggest that the frequency of approximately 27% to 39% of people with PD have the presence of abnormal bladder function. Despite the prevalence of urinary dysfunction , the actual urinary incontinence is relatively rare. Problems that commonly occur are frequent nighttime urination (up 86%), urinary urgency (33-71%), urinary frequency (16- 68%) and urge incontinence. Treatment of this dysfunction must be customized with the therapy for the treatment of PD. Each patient should be excluded from malignant urological diseases (bladder cancer, prostate cancer). The goals of diagnosis and treatment are controlling the unwilling urination, completely emptying the bladder and the protection of renal function.